Neoplasms

New Results From the Landmark Prospective CIRCULATE Trial Expand Clinical Utility of the Signatera® MRD Test in Colorectal Cancer

Retrieved on: 
Friday, July 2, 2021

"We believe that personalized MRD testing is the future and will improve treatment decisions for tens of thousands of colorectal cancer patients in Japan and around the world."

Key Points: 
  • "We believe that personalized MRD testing is the future and will improve treatment decisions for tens of thousands of colorectal cancer patients in Japan and around the world."
  • Longitudinal MRD-positivity was significantly associated with inferior disease-free survival (hazard ratio = 46.8) and Signatera demonstrated a relapse sensitivity of 93.1%.
  • Signatera is a custom-built circulating tumor DNA (ctDNA) test for treatment monitoring and molecular residual disease (MRD) assessment in patients previously diagnosed with cancer.
  • Signatera test performance has been clinically validated in multiple cancer types including colorectal, non-small cell lung, breast, and bladder cancers.

CicloMed Announces Initiation of Phase 1B Trial of Fosciclopirox in Newly Diagnosed and Recurrent Urothelial Cancer Patients

Retrieved on: 
Tuesday, June 29, 2021

We are excited to have initiated this Phase 1B trial of fosciclopirox in newly diagnosed and recurrent urothelial cancer patients scheduled for transurethral resection of bladder tumors, said Tammy Ham, CEO of CicloMed.

Key Points: 
  • We are excited to have initiated this Phase 1B trial of fosciclopirox in newly diagnosed and recurrent urothelial cancer patients scheduled for transurethral resection of bladder tumors, said Tammy Ham, CEO of CicloMed.
  • We believe that fosciclopirox provides strong potential to improve treatment outcomes for patients with bladder cancer.
  • In September 2020, CicloMed was awarded a Phase II Small Business Innovation Research (SBIR) grant by the National Cancer Institute (NCI), enabling the Phase 1B trial.
  • The initiation of this Phase 1B trial enables us to characterize the pharmacologic activity and mechanisms of fosciclopirox action following treatment in urothelial cancer patients, Weir added.

Elicio Therapeutics Announces Initiation of Its Phase 1/2 Dose-Escalation Study of ELI-002 (AMPLIFY-201) in KRAS-Driven Cancers

Retrieved on: 
Tuesday, June 29, 2021

AMPLIFY-201 is a Phase 1/2 clinical trial of ELI-002 in patients with solid tumors, including colorectal cancer, or CRC, or pancreatic ductal adenocarcinoma, or PDAC.

Key Points: 
  • AMPLIFY-201 is a Phase 1/2 clinical trial of ELI-002 in patients with solid tumors, including colorectal cancer, or CRC, or pancreatic ductal adenocarcinoma, or PDAC.
  • Following an initial dose escalation phase, we intend to evaluate the potential of ELI-002 as a treatment for a number of KRAS-mutated cancers.
  • Elicio Therapeutics is a clinical-stage biotechnology company developing a pipeline of novel immunotherapies for the treatment of cancer and other diseases.
  • Elicio is engineering lymph node targeted AMPlifiers, immunomodulators, adjuvants and vaccines for an array of aggressive cancers and infectious diseases.

Insights on the Myeloproliferative Neoplasm Drugs Global Market to 2027 - Featuring Gamida Cell, Sierra Oncology & CTI BioPharma Among Others - ResearchAndMarkets.com

Retrieved on: 
Monday, June 28, 2021

The "Myeloproliferative Neoplasm Drugs Market - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Myeloproliferative Neoplasm Drugs Market - Size, Share, Outlook, and Opportunity Analysis, 2019 - 2027" report has been added to ResearchAndMarkets.com's offering.
  • The various drug classes indicated for the treatment of myeloproliferative neoplasm are demethylation agents, tyrosine kinase inhibitor, multikinase inhibitors, JAK2 inhibitor, and others.
  • Key companies are focusing on strategies such as mergers and acquisitions, which is expected to drive the global myeloproliferative neoplasm drugs market growth.
  • Moreover, key players are focusing on product launches and product approvals to strengthen their presence in the global myeloproliferative neoplasm drugs market.

Adenoid Cystic Carcinoma Pipeline Insight Report 2021: Ayala Pharmaceuticals, CureVac, Elevar Therapeutics, Actuate Therapeutics, AL101, CV8102, Rivoceranib, 9-ING-41 - ResearchAndMarkets.com

Retrieved on: 
Friday, June 25, 2021

The "Adenoid Cystic Carcinoma - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Adenoid Cystic Carcinoma - Pipeline Insight, 2021" drug pipelines has been added to ResearchAndMarkets.com's offering.
  • This "Adenoid cystic carcinoma - Pipeline Insight, 2021" report provides comprehensive insights about 5+ companies and 5+ pipeline drugs in Adenoid cystic carcinoma pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Adenoid cystic carcinoma R&D.
  • Adenoid cystic carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration.

Incyte Announces Outcome of FDA Oncologic Drugs Advisory Committee (ODAC) Meeting Reviewing Retifanlimab as a Treatment for Patients with Squamous Cell Carcinoma of the Anal Canal (SCAC)

Retrieved on: 
Thursday, June 24, 2021

We continue to believe that retifanlimab can provide an additional, much-needed option for these patients based on the favorable benefit/risk shown in our trial.

Key Points: 
  • We continue to believe that retifanlimab can provide an additional, much-needed option for these patients based on the favorable benefit/risk shown in our trial.
  • Additional indications in late-stage development include platinum-nave squamous cell carcinoma of the anal canal (SCAC), microsatellite instability-high endometrial cancer, Merkel cell carcinoma and non-small cell lung cancer.
  • Additional indications in late-stage development include platinum-nave squamous cell carcinoma of the anal canal (SCAC), microsatellite instability-high endometrial cancer, Merkel cell carcinoma and non-small cell lung cancer.
  • The role of systemic chemotherapy and multidisciplinary management in improving the overall survival of patients with metastatic squamous cell carcinoma of the anal canal.

Moleculin Announces First Subject Enrolled and Dosed in Phase 1b/2 Clinical Trial of Annamycin for the Treatment of Sarcoma Lung Metastases

Retrieved on: 
Monday, June 21, 2021

Phase 1b/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma (STS) lung metastases.

Key Points: 
  • Phase 1b/2 clinical trial evaluating Annamycin for the treatment of soft tissue sarcoma (STS) lung metastases.
  • Soft tissue sarcomas are the most common form of sarcoma, accounting for an estimated 130,000 incident cases per year worldwide.
  • For more information about the Phase 1b/2 study evaluating Annamycin for the treatment of STS lung metastases, please visit clinicaltrials.gov and reference identifier NCT04887298.
  • Annamycin is currently in development for the treatment of relapsed or refractory acute myeloid leukemia (AML) and soft tissue sarcoma (STS) lung metastases.

Foresight Diagnostics to Present a Vision of the New Standard of Lymphoma MRD Detection at the 16th International Conference on Malignant Lymphoma

Retrieved on: 
Thursday, June 17, 2021

The oral presentation demonstrates the utility of Foresight Diagnostics proprietary PhasED-Seq technology to improve MRD detection rates in DLBCL patients in low-disease burden settings.

Key Points: 
  • The oral presentation demonstrates the utility of Foresight Diagnostics proprietary PhasED-Seq technology to improve MRD detection rates in DLBCL patients in low-disease burden settings.
  • We believe that such early detection constitutes the future standard for ctDNA-guided patient monitoring and treatment in the clinic and for drug development applications.
  • Circulating tumor DNA (ctDNA) detection has prognostic value in DLBCL and has the potential to change the management of lymphoma in the clinic.
  • But detection is still challenging in low-disease burden states with existing methods, such as MRD detection at the end of therapy.

St. Baldrick's Works to Give Kids with Cancer More Than Five Years

Retrieved on: 
Tuesday, June 15, 2021

But, according to the National Cancer Institute, the five-year survival rate for childhood cancers has risen to 84% overall.

Key Points: 
  • But, according to the National Cancer Institute, the five-year survival rate for childhood cancers has risen to 84% overall.
  • That is meaningful in scientific terms, but it's just not good enough for a child with cancer.
  • While hitting the five-year milestone is worth celebrating, some will die later, either of their cancer or the effects of their treatment.
  • But, for other types of childhood cancer like osteosarcoma, a cancer of the bone treatment is not much different today than it was decades ago.

HiberCell Initiates Phase 1a Clinical Trial of HC-5404-FU, an ER Stress Modulator

Retrieved on: 
Thursday, June 10, 2021

HC-5404-FU is an endoplasmic reticulum (ER) stress modulator, and the Investigational New Drug (IND) application received the greenlight from the U.S. Food and Drug Administration (FDA) in late 2020.

Key Points: 
  • HC-5404-FU is an endoplasmic reticulum (ER) stress modulator, and the Investigational New Drug (IND) application received the greenlight from the U.S. Food and Drug Administration (FDA) in late 2020.
  • The Phase 1a trial is designed as a dose escalation study across patients with specific tumor types, inclusive of renal cell carcinoma (RCC), gastric cancer (GC), breast cancer (MBC), and small-cell lung cancer (SCLC).
  • The initiation of this first-in-human study is a significant milestone for HiberCell as we move our platform of stress modulators into the clinic.
  • To that end, HiberCell is developing therapies that blunt the omnipresent stress-mediated adaptive response of cancer cells.